Medium Size European Pharma Company

The client was preparing to launch a novel 5-HT3 anti-emetic into the post operative nausea and vomiting (PONV) market in the US, and Japan, around the time of ondasetron generic availability, and needed to know the size of the available patient population and the likelihood of use of the client’s new product.

Our Solution

• GlobalData used a chart audit process to identify the standard of care for pre and post operative prophylaxis and treatment.
• The data gathered in the chart audit was compared against government surgery statistics and product sales data to chart the breakdown of use of the various anti-emetics.
• We used primary research to determine the switching rate from Zofran and other branded anti-emetics to generic ondansetrons.
• We also explored the likely uptake of sublingual ondasetron and transdermal granisetron

Outcome

Based on the research, GlobalData identified the probable market size for the client’s product and recommended clinical and commercial steps to garner managed care coverage and optimize uptake.